Genetics of High-Altitude Pulmonary Edema.

High-altitude pulmonary edema Hypoxia Mutations Polymorphisms Pulmonary artery pressure Pulmonary hypertension

Journal

Heart failure clinics
ISSN: 1551-7136
Titre abrégé: Heart Fail Clin
Pays: United States
ID NLM: 101231934

Informations de publication

Date de publication:
Jan 2023
Historique:
entrez: 26 11 2022
pubmed: 27 11 2022
medline: 30 11 2022
Statut: ppublish

Résumé

High-altitude pulmonary edema (HAPE) is the main cause of nontraumatic death at high altitude. HAPE development is not only related to the mode and speed of ascent and the maximum altitude reached, but also individual susceptibility plays an important role. In susceptible individuals, hypoxic pulmonary vasoconstriction leads to exaggerated elevated pulmonary arterial pressures and capillary leakage in the lungs. Thus, this review provides an overview of studies investigating the genetic background in HAPE susceptibles by focusing on specific variants, entire genes, genome-wide signatures, or family studies.

Identifiants

pubmed: 36435576
pii: S1551-7136(22)00051-4
doi: 10.1016/j.hfc.2022.07.002
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

89-96

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Christina A Eichstaedt (CA)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstraße 1, Heidelberg 69126, Germany; Laboratory for Molecular Genetic Diagnostics, Institute of Human Genetics, Heidelberg University, Im Neuenheimer Feld 366, Heidelberg 69120, Germany; Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany. Electronic address: christina.eichstaedt@med.uni-heidelberg.de.

Nicola Benjamin (N)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstraße 1, Heidelberg 69126, Germany; Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.

Ding Cao (D)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstraße 1, Heidelberg 69126, Germany; Laboratory for Molecular Genetic Diagnostics, Institute of Human Genetics, Heidelberg University, Im Neuenheimer Feld 366, Heidelberg 69120, Germany.

Eglė Palevičiūtė (E)

Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius University, Santariskiu-2, Vilnius 08661, Lithuania.

Ekkehard Grünig (E)

Centre for Pulmonary Hypertension, Thoraxklinik Heidelberg gGmbH at Heidelberg University Hospital, Röntgenstraße 1, Heidelberg 69126, Germany; Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH